Appian International Research Enters Second Year with Ongoing Trials in Seven Countries
Appian International Research Enters Second Year with Ongoing Trials in Seven Countries
CHARLOTTE, NC, June 29, 2007-This week, Appian International Research, Inc. announced plans to expand its generic pharmaceuticals development services as the company enters its second year.
“Appian International Research as a company is still relatively new to the industry, but our team certainly isn’t,” explained Appian’s President, Dr. Grier Harris.
“Appian International Research is the outgrowth of Appian Services, a consulting firm that we established in 2003 to provide contract development services to generic and small Pharma companies. We help our clients manage strategic development plans, designed study protocols, compiled reports, and performed site audits, whatever it took to help them overcome the hurdles inherent in pharmaceutical product development. As business grew, we decided to focus on our expanding network of international resources and broaden our range of services.”
“Our specialty, of course, is the design and management of clinical endpoint bioequivalence trials, the sort of trials that the FDA’s Office of Generic Drugs requires for the approval of topically active drugs. Most of our early work has been in dermatological products, but we are currently expanding into some other therapeutic areas that will take advantage of the many years of experience that we have in topical drug development.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
